Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Journal of Medicinal Chemistry|January 1, 1976
Synthesis and biological actions of 2-substituted quinolizidinesT L Lemke, M B CramerJournal of Pharmaceutical Sciences|March 1, 1976
Phosphorus-nitrogen compounds XIX: distribution of 32P and effect of an active oncolytic on intracerebral leukemia in rodentsL A Cates, M B CramerJournal of Medicinal Chemistry|January 1, 1978
Phosphorus-nitrogen compounds. 21. Murine oncolytic and antifertility effect of adamantylaziridine compoundsL A Cates, M B Cramer, L WilliamsJournal of Pharmaceutical Sciences|October 1, 1978
Heterocyclic tricycles as potential CNS agents I: 4-aminoalkylindeno[1,2-c]pyrazolesT L Lemke, M B Cramer, K ShanmugamThe Journal of Pharmacy and Pharmacology|May 1, 1978
Rectal absorption of homatropine [14C]methylbromide in the ratM B Cramer, L A Cates, D E ClarkeCancer Chemotherapy and Pharmacology|January 29, 1999
Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjectsD C Dimmitt, M B Cramer, A Keung, et al.Journal of Medicinal Chemistry|October 1, 1981
beta-Adrenergic blocking agents. alpha- and gamma-methyl(aryloxy)propanolaminesT L Lemke, M B Cramer, S W Adamski, et al.American Journal of Therapeutics|July 29, 1999
Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapyC L Lippert, D C Dimmitt, L Martin, et al.Cancer Investigation|January 1, 1997
A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapyB S Kasimis, E Tapazoglou, P Schulman, et al.Cancer Chemotherapy and Pharmacology|January 1, 1996
A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesisG S Harman, G A Omura, K Ryan, et al.Pageof 2